中国药业2023，Vol.32Issue(24)：19-24,6.DOI:10.3969/j.issn.1006-4931.2023.24.005
《国家医保目录》待谈判中成药药物经济学研究系统评价
Pharmacoeconomics Study of Chinese Patent Medicines to be Negotiated for National Reimbursement Drug List:A Systematic Review
摘要
Abstract
Objective To investigate the economy of Chinese patent medicines to be negotiated in the Drug List Through the Preliminary Form of Examination in the National Reimbursement Drug List in 2023(hereinafter referred to as the Drug List).Methods The pharmacoeconomics studies related to Chinese patent medicines to be negotiated in the Drug List in the PubMed,CNKI,WanFang and SinoMed from the inception of each database to August 2023 were systematically searched,the basic information,research summary,pharmacoeconomics evaluation methods and content of studies were summarized,and the quality of studies was evaluated by the Consolidated Health Economic Evaluation Reporting Standards(CHEERS)checklist.Results A total of 31 studies were included,all in Chinese,involving seven Chinese patent medicines to be negotiated in the Drug List(Shenyi Capsules,Danhong Injection,Compound Danshen Dropping Pills,Diterpene Ginkgolide Meglumine Injection,Ginkgolide Injection,Salvianolate Lyophilized Injection and Yiqi Fumai Injection),of which 14 studies showed that the drugs to be evaluated were economical.The CHEERS checklist evaluation showed an average score of 13.3 points for the included studies,with a median score of 11.5 points.Conclusion The existing studies show that high-quality pharmacoeconomics studies to support Chinese patent medicines to be negotiated in the Drug List included in the National Reimbursement Drug List were lacked,so it is urgent to improve the quality of studies.关键词
中成药/药物经济学/待谈判药品/《国家医保目录》/系统评价Key words
Chinese patent medicine/pharmacoeconomics/drug to be negotiated/National Reimbursement Drug List/systematic review分类
医药卫生引用本文复制引用
郑雅婷,谭重庆,王勇..《国家医保目录》待谈判中成药药物经济学研究系统评价[J].中国药业,2023,32(24):19-24,6.基金项目
国家自然科学基金[82073818]. （）
